Hypolite Muhindo Mavoko1, Carolyn Nabasumba2, Raquel Inocêncio da Luz3, Halidou Tinto4, Umberto D'Alessandro5, Andrew Kambugu6, Vito Baraka7, Anna Rosanas-Urgell8, Pascal Lutumba9, Jean-Pierre Van Geertruyden3. 1. Département de Médecine Tropicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, DR Congo; Epidemiology for Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. Electronic address: mavoko@yahoo.com. 2. Epidemiology for Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Infectious Disease Institute, University of Makerere, Kampala, Uganda; Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda. 3. Epidemiology for Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 4. Centre Muraz/Institut de Recherche en Sciences de la Santé, Bobo Dioulasso, Burkina Faso. 5. Institute of Tropical Medicine, Antwerp, Belgium; London School of Hygiene & Tropical Medicine, London, UK; Medical Research Council, The Gambia Unit, Banjul, The Gambia. 6. Infectious Disease Institute, University of Makerere, Kampala, Uganda. 7. Epidemiology for Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; National Institute for Medical Research, Tanga Research Centre, Tanga, Tanzania. 8. Institute of Tropical Medicine, Antwerp, Belgium. 9. Département de Médecine Tropicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, DR Congo.
Abstract
BACKGROUND:Quinine or alternative artemisinin-based combination treatment (ACT) is the recommended rescue treatment for uncomplicated malaria. However, patients are often re-treated with the same ACT though it is unclear whether this is the most suitable approach. We assessed the efficacy and safety of re-treating malaria patients with uncomplicated failures with the same ACT used for the primary episode, compared with other rescue treatments. METHODS: This was a bicentre, open-label, randomised, three-arm phase 3 trial done in Lisungi health centre in DR Congo, and Kazo health centre in Uganda in 2012-14. Children aged 12-60 months with recurrent malaria infection after treatment with the first-line ACT were randomly assigned to either re-treatment with the same first-line ACT, an alternative ACT, which were given for 3 days, or quinine-clindamycin (QnC), which was given for 5-7 days, following a 2:2:1 ratio. Randomisation was done by computer-generated randomisation list in a block design by country. The three treatment groups were assumed to have equivalent efficacy above 90%. Both the research team and parents or guardians were aware of treatment allocation. The primary outcome was the proportion of patients with an adequate clinical and parasitological response (ACPR) at day 28, in the per-protocol population. This trial was registered under the numbers NCT01374581 in ClinicalTrials.gov and PACTR201203000351114 in the Pan African Clinical Trials Registry. FINDINGS:From May 22, 2012, to Jan 31, 2014, 571 children were included in the trial. 240 children were randomly assigned to the re-treatment ACT group, 233 to the alternative ACT group, and 98 to the QnC group. 500 children were assessed for the primary outcome. 71 others were not included because they did not complete the follow-up or PCR genotyping result was not conclusive. The ACPR response was similar in the three groups: 91·4% (95% CI 87·5-95·2) for the re-treatment ACT, 91·3% (95% CI 87·4-95·1) for the alternative ACT, and 89·5% (95% CI 83·0-96·0) for QnC. The estimates for rates of malaria recrudescence in the three treatment groups were similar (log-rank test: χ2=0·22, p=0·894). Artemether-lumefantrine was better tolerated than QnC (p=0·0005) and artesunate-amodiaquine (p<0·0001) in the modified intention-to-treat analysis. No serious adverse events were observed. The most common adverse events reported in the re-treatment ACT group were anorexia (31 [13%] of 240 patients), asthenia (20 [8%]), coughing (16 [7%]), abnormal behaviour (13 [5%]), and diarrhoea (12 [5%]). Anorexia (13 [6%] of 233 patients) was the most frequently reported adverse event in the alternative ACT group. The most commonly reported adverse events in the QnC group were anorexia (12 [12%] of 98 patients), abnormal behaviour (6 [6%]), asthenia (6 [6%]), and pruritus (5 [5%]). INTERPRETATION: Re-treatment with the same ACT shows similar efficacy as recommended rescue treatments and could be considered for rescue treatment for Plasmodium falciparum malaria. However, the effect of this approach on the selection of resistant strains should be monitored to ensure that re-treatment with the same ACT does not contribute to P falciparum resistance. FUNDING: Fonds Wetenschappelijk Onderzoek, Vlaamse Interuniversitaire Raad-Universitaire Ontwikkelings Samenwerking, European and Developing Countries Clinical Trials Partnership, and the Belgian Technical Cooperation-Programme d'Etudes et d'Expertises-in the Democratic Republic of Congo.
RCT Entities:
BACKGROUND:Quinine or alternative artemisinin-based combination treatment (ACT) is the recommended rescue treatment for uncomplicated malaria. However, patients are often re-treated with the same ACT though it is unclear whether this is the most suitable approach. We assessed the efficacy and safety of re-treating malariapatients with uncomplicated failures with the same ACT used for the primary episode, compared with other rescue treatments. METHODS: This was a bicentre, open-label, randomised, three-arm phase 3 trial done in Lisungi health centre in DR Congo, and Kazo health centre in Uganda in 2012-14. Children aged 12-60 months with recurrent malaria infection after treatment with the first-line ACT were randomly assigned to either re-treatment with the same first-line ACT, an alternative ACT, which were given for 3 days, or quinine-clindamycin (QnC), which was given for 5-7 days, following a 2:2:1 ratio. Randomisation was done by computer-generated randomisation list in a block design by country. The three treatment groups were assumed to have equivalent efficacy above 90%. Both the research team and parents or guardians were aware of treatment allocation. The primary outcome was the proportion of patients with an adequate clinical and parasitological response (ACPR) at day 28, in the per-protocol population. This trial was registered under the numbers NCT01374581 in ClinicalTrials.gov and PACTR201203000351114 in the Pan African Clinical Trials Registry. FINDINGS: From May 22, 2012, to Jan 31, 2014, 571 children were included in the trial. 240 children were randomly assigned to the re-treatment ACT group, 233 to the alternative ACT group, and 98 to the QnC group. 500 children were assessed for the primary outcome. 71 others were not included because they did not complete the follow-up or PCR genotyping result was not conclusive. The ACPR response was similar in the three groups: 91·4% (95% CI 87·5-95·2) for the re-treatment ACT, 91·3% (95% CI 87·4-95·1) for the alternative ACT, and 89·5% (95% CI 83·0-96·0) for QnC. The estimates for rates of malaria recrudescence in the three treatment groups were similar (log-rank test: χ2=0·22, p=0·894). Artemether-lumefantrine was better tolerated than QnC (p=0·0005) and artesunate-amodiaquine (p<0·0001) in the modified intention-to-treat analysis. No serious adverse events were observed. The most common adverse events reported in the re-treatment ACT group were anorexia (31 [13%] of 240 patients), asthenia (20 [8%]), coughing (16 [7%]), abnormal behaviour (13 [5%]), and diarrhoea (12 [5%]). Anorexia (13 [6%] of 233 patients) was the most frequently reported adverse event in the alternative ACT group. The most commonly reported adverse events in the QnC group were anorexia (12 [12%] of 98 patients), abnormal behaviour (6 [6%]), asthenia (6 [6%]), and pruritus (5 [5%]). INTERPRETATION: Re-treatment with the same ACT shows similar efficacy as recommended rescue treatments and could be considered for rescue treatment for Plasmodium falciparum malaria. However, the effect of this approach on the selection of resistant strains should be monitored to ensure that re-treatment with the same ACT does not contribute to P falciparum resistance. FUNDING: Fonds Wetenschappelijk Onderzoek, Vlaamse Interuniversitaire Raad-Universitaire Ontwikkelings Samenwerking, European and Developing Countries Clinical Trials Partnership, and the Belgian Technical Cooperation-Programme d'Etudes et d'Expertises-in the Democratic Republic of Congo.
Authors: Henk Dfh Schallig; Halidou Tinto; Patrick Sawa; Harparkash Kaur; Stephan Duparc; Deus S Ishengoma; Pascal Magnussen; Michael Alifrangis; Colin J Sutherland Journal: BMJ Glob Health Date: 2017-08-30
Authors: Sam Proesmans; Freddy Katshongo; John Milambu; Blaise Fungula; Hypolite Muhindo Mavoko; Steve Ahuka-Mundeke; Raquel Inocêncio da Luz; Marjan Van Esbroeck; Kevin K Ariën; Lieselotte Cnops; Birgit De Smet; Pascal Lutumba; Jean-Pierre Van Geertruyden; Veerle Vanlerberghe Journal: PLoS Negl Trop Dis Date: 2019-09-05
Authors: Milan Trojánek; Vyacheslav Grebenyuk; Lenka Richterová; Ivana Zicklerová; Eva Nohýnková; Zdenka Manďáková; Jakub Kantor; Hana Roháčová; František Stejskal Journal: Malar J Date: 2022-09-06 Impact factor: 3.469
Authors: Giulia Rathmes; Susan F Rumisha; Tim C D Lucas; Katherine A Twohig; Andre Python; Michele Nguyen; Anita K Nandi; Suzanne H Keddie; Emma L Collins; Jennifer A Rozier; Harry S Gibson; Elisabeth G Chestnutt; Katherine E Battle; Georgina S Humphreys; Punam Amratia; Rohan Arambepola; Amelia Bertozzi-Villa; Penelope Hancock; Justin J Millar; Tasmin L Symons; Samir Bhatt; Ewan Cameron; Philippe J Guerin; Peter W Gething; Daniel J Weiss Journal: Malar J Date: 2020-10-20 Impact factor: 2.979